Chaofu Ke1, Xiaohong Zhu2, Yuxia Zhang1, Yueping Shen3. 1. Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, 199 Renai Road, Suzhou, 215123, People's Republic of China. 2. Suzhou Industrial Park Centers for Disease Control and Prevention (Institute of Health Inspection and Supervision), Suzhou, 215021, Jiangsu, People's Republic of China. 3. Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, 199 Renai Road, Suzhou, 215123, People's Republic of China. shenyueping@suda.edu.cn.
Abstract
BACKGROUND: Hypertension and dyslipidemia are two main risk factors for cardiovascular diseases (CVD). Moreover, their coexistence predisposes individuals to a considerably increased risk of CVD. However, the regulatory mechanisms involved in hypertension and dyslipidemia as well as their interactions are incompletely understood. OBJECTIVES: The aims of our study were to identify metabolic biomarkers and pathways for hypertension and dyslipidemia, and compare the metabolic patterns between hypertension and dyslipidemia. METHODS: In this study, we performed metabolomic investigations into hypertension and dyslipidemia based on a "healthy" UK population. Metabolomic data from the Husermet project were acquired by gas chromatography-mass spectrometry and ultra-performance liquid chromatography-mass spectrometry. Both univariate and multivariate statistical methods were used to facilitate biomarker selection and pathway analysis. RESULTS: Serum metabolic signatures between individuals with and without hypertension or dyslipidemia exhibited considerable differences. Using rigorous selection criteria, 26 and 46 metabolites were identified as potential biomarkers of hypertension and dyslipidemia respectively. These metabolites, mainly involved in fatty acid metabolism, glycerophospholipid metabolism, alanine, aspartate and glutamate metabolism, are implicated in insulin resistance, vascular remodeling, macrophage activation and oxidised LDL formation. Remarkably, hypertension and dyslipidemia exhibit both common and distinct metabolic patterns, revealing their independent and synergetic biological implications. CONCLUSION: This study identified valuable biomarkers and pathways for hypertension and dyslipidemia, and revealed common and different metabolic patterns between hypertension and dyslipidemia. The information provided in this study could shed new light on the pathologic mechanisms and offer potential intervention targets for hypertension and dyslipidemia as well as their related diseases.
BACKGROUND:Hypertension and dyslipidemia are two main risk factors for cardiovascular diseases (CVD). Moreover, their coexistence predisposes individuals to a considerably increased risk of CVD. However, the regulatory mechanisms involved in hypertension and dyslipidemia as well as their interactions are incompletely understood. OBJECTIVES: The aims of our study were to identify metabolic biomarkers and pathways for hypertension and dyslipidemia, and compare the metabolic patterns between hypertension and dyslipidemia. METHODS: In this study, we performed metabolomic investigations into hypertension and dyslipidemia based on a "healthy" UK population. Metabolomic data from the Husermet project were acquired by gas chromatography-mass spectrometry and ultra-performance liquid chromatography-mass spectrometry. Both univariate and multivariate statistical methods were used to facilitate biomarker selection and pathway analysis. RESULTS: Serum metabolic signatures between individuals with and without hypertension or dyslipidemia exhibited considerable differences. Using rigorous selection criteria, 26 and 46 metabolites were identified as potential biomarkers of hypertension and dyslipidemia respectively. These metabolites, mainly involved in fatty acid metabolism, glycerophospholipid metabolism, alanine, aspartate and glutamate metabolism, are implicated in insulin resistance, vascular remodeling, macrophage activation and oxidised LDL formation. Remarkably, hypertension and dyslipidemia exhibit both common and distinct metabolic patterns, revealing their independent and synergetic biological implications. CONCLUSION: This study identified valuable biomarkers and pathways for hypertension and dyslipidemia, and revealed common and different metabolic patterns between hypertension and dyslipidemia. The information provided in this study could shed new light on the pathologic mechanisms and offer potential intervention targets for hypertension and dyslipidemia as well as their related diseases.
Authors: Jennifer M Rutkowsky; Trina A Knotts; Kikumi D Ono-Moore; Colin S McCoin; Shurong Huang; Dina Schneider; Shamsher Singh; Sean H Adams; Daniel H Hwang Journal: Am J Physiol Endocrinol Metab Date: 2014-04-22 Impact factor: 4.310
Authors: Ruben O Halperin; Howard D Sesso; Jing Ma; Julie E Buring; Meir J Stampfer; J Michael Gaziano Journal: Hypertension Date: 2005-12-12 Impact factor: 10.190
Authors: S Kalmijn; D Foley; L White; C M Burchfiel; J D Curb; H Petrovitch; G W Ross; R J Havlik; L J Launer Journal: Arterioscler Thromb Vasc Biol Date: 2000-10 Impact factor: 8.311
Authors: Takahiko Nakagawa; Hanbo Hu; Sergey Zharikov; Katherine R Tuttle; Robert A Short; Olena Glushakova; Xiaosen Ouyang; Daniel I Feig; Edward R Block; Jaime Herrera-Acosta; Jawaharlal M Patel; Richard J Johnson Journal: Am J Physiol Renal Physiol Date: 2005-10-18
Authors: Royston Goodacre; Seetharaman Vaidyanathan; Warwick B Dunn; George G Harrigan; Douglas B Kell Journal: Trends Biotechnol Date: 2004-05 Impact factor: 19.536
Authors: Lloyd W Sumner; Alexander Amberg; Dave Barrett; Michael H Beale; Richard Beger; Clare A Daykin; Teresa W-M Fan; Oliver Fiehn; Royston Goodacre; Julian L Griffin; Thomas Hankemeier; Nigel Hardy; James Harnly; Richard Higashi; Joachim Kopka; Andrew N Lane; John C Lindon; Philip Marriott; Andrew W Nicholls; Michael D Reily; John J Thaden; Mark R Viant Journal: Metabolomics Date: 2007-09 Impact factor: 4.290
Authors: Moritz V Warmbrunn; Annefleur M Koopen; Nicolien C de Clercq; Pieter F de Groot; Ruud S Kootte; Kristien E C Bouter; Kasper W Ter Horst; Annick V Hartstra; Mireille J Serlie; Mariette T Ackermans; Maarten R Soeters; Daniel H van Raalte; Mark Davids; Max Nieuwdorp; Albert K Groen Journal: Metabolites Date: 2021-04-13